Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
The Fly
Piper Sandler healthcare analysts hold an analyst/industry conference call
11h ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital
14d ago
ATYR
Premium
The Fly
Wells Fargo downgrades aTyr Pharma on efzofitimod Phase 3 failure
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Neutral from Buy at Lucid Capital
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Hold from Buy at JonesResearch
15d ago
ATYR
Premium
Ratings
Hold Rating Issued for aTyr Pharma Amid Uncertainty Over Efzofitimod’s Trial Results and Future
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Market Perform from Outperform at Leerink
15d ago
ATYR
Premium
The Fly
aTyr Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
15d ago
ATYR
Premium
Ratings
Buy Rating for aTyr Pharma Despite Phase 3 Trial Setback, Focus on Quality of Life Improvements
15d ago
ATYR
Premium
The Fly
Leerink sees low chance of aTyr advancing efzofitimod after miss
15d ago
ATYR
Premium
Company Announcements
aTyr Pharma Reveals Phase 3 Study Results
15d ago
8K
ATYR
Premium
The Fly
aTyr Pharma announces results from Phase 3 EFZO-FIT study
15d ago
ATYR
Premium
The Fly
aTyr Pharma Inc put volume heavy and directionally bearish
21d ago
ATYR
Premium
The Fly
aTyr Pharma Inc put volume heavy and directionally bearish
26d ago
ATYR
Premium
The Fly
aTyr Pharma price target raised to $17 from $9 at Jefferies
1M ago
ATYR
Premium
Ratings
Optimistic Buy Rating for aTyr Pharma Amid Promising EFZO-FIT Trial Prospects
1M ago
ATYR
Premium
Ratings
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study
2M ago
ATYR
Premium
Ratings
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach
2M ago
ATYR
Premium
Ratings
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma
2M ago
ATYR
Premium
Ratings
aTyr Pharma: Strong Financials and Promising Therapeutic Candidate Drive Buy Rating
2M ago
ATYR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
